Related Experiment Videos
Hepatic adverse reactions associated with nefazodone
1University Health Network, University of Toronto, Toronto, Ontario. donna.stewart@uhn.on.ca
Summary
Nefazodone (Serzone) has been linked to severe liver injury, with 32 cases reported in Canada. Most cases were severe, occurring within six months, highlighting the need for caution when prescribing this antidepressant.
Area of Science:
- Pharmacovigilance
- Hepatology
- Clinical Pharmacology
Background:
- Increasing international reports of nefazodone-associated hepatotoxicity since 1999.
- A 2001 Canadian safety advisory highlighted rare, severe liver injury cases linked to nefazodone.
- Need to assess the prevalence of nefazodone adverse drug reactions in Canada.
Purpose of the Study:
- To determine the prevalence of hepatotoxicity associated with nefazodone in Canada.
- To analyze reported hepatic complications from the Canadian Adverse Drug Reaction Monitoring Programme (CADRMP) database.
Main Methods:
- Analysis of the CADRMP database for nefazodone-related hepatic complications.
- Inclusion of data from drug marketing to June 30, 2001.
Main Results:
- 32 cases of nefazodone-associated liver injury identified, with 81.3% classified as severe.
- Most affected patients were women, aged 30-69, with injury onset within 6 months.
- Outcomes included recovery, ongoing issues, and severe events like hepatic failure and necrosis.
Conclusions:
- The CADRMP database likely underrepresents actual adverse drug reactions.
- Caution is advised when prescribing nefazodone, especially with CYP4503A4 metabolized drugs, and it should be avoided in patients with pre-existing liver disease.
- Regular liver function tests and patient education on hepatotoxicity symptoms are crucial for nefazodone therapy.